Pfizer CEO Read says pharma has a bad rep; Shareholders OK Actavis, Warner Chilcott deal; New cancer drugs make care complex;

@FiercePharma: Italy's Recordati set to buy Spain's Laboratorios Casen Fleet for $122.4M. ICYMI yesterday | Follow @FiercePharma

@EricPFierce: KKR looks to buy stake in Gland Pharma as emotions are running high in India over loss of domestic cos. Report | Follow @EricPFierce

@CarlyHFierce: On why silence from Vivus is not golden. More via Seeking Alpha | Follow @CarlyHFierce

> Pfizer ($PFE) CEO Ian Read acknowledged the industry is not thought of highly by the public, despite providing life-saving meds. Story

> Shareholders have given final approval for generic drugmaker Actavis ($ACT) to buy Warner Chilcott ($WCRX) for $8.5 billion. Report

> India is asking drugmakers there to step up with more production of medicines for tropical diseases. Story

> Perrigo ($PRGO) says the FDA has approved its generic of Johnson & Johnson's ($JNJ) Children's Zyrtec Allergy Syrup. Release

> Biogen Idec ($BIIB) and Amicus Therapeutics ($FOLD) have a new agreement to work on drugs for Parkinson's disease. Story

Medical Device News

@FierceMedDev: Popular yesterday: Intuitive's surgical robots slammed in another study. Article | Follow @FierceMedDev

@DamianFierce: Dako got an FDA warning letter at the plant where it makes its Herceptin companion diagnostic. News | Follow @DamianFierce

@MarkHFierce: Baxter snatched up a tiny startup after closing a nearly $4B deal for Gambro. ICYMI yesterday | Follow @MarkHFierce

> Quest, LabCorp defrauded Medicaid, lawsuit says. News

> Spider silk + carbon nanotubes = next-gen med device part. Item

> KKR might want some help buying Panasonic's $1.5B health biz. Story

Biotech News

@FierceBiotech: ICYMI yesterday: Is there a major R&D overhaul coming at Merck, or just more streamlining? Article | Follow @FierceBiotech

@JohnCFierce: ICYMI: FDA experts endorse new COPD blockbuster from GlaxoSmithKline, Theravance. Story | Follow @JohnCFierce

@EmilyMFierce: This week's issue of FierceBiotech Research: Parkinson's research gets boost; Drug combo tackles coronavirus. Check it out | Follow @EmilyMFierce

@Ry_McBride: Civitas scoops up $38M B round for inhaled Parkinsons drug. News | Follow @Ry_McBride

> OvaScience shares blitzed after FDA steps in to supervise lead product. News

> Merck laterals cancer drug to hungry AstraZeneca, focuses on star programs. Article

> Chimerix reports PhII failure for lead antiviral. Item

Drug Delivery News

@MichaelGFierce: Nanodiamonds deliver brain cancer drugs safely, UCLA team shows. Report | Follow @MichaelGFierce

> Activaero, Chiesi team up for cystic fibrosis drug-device research. News

> Low-cost microspheres take short-lived cancer drugs to brain. Article

> Oramed wins Chinese patent for oral core technology. Item

> CeQur closes $27M round to fund insulin delivery device. Story

Diagnostics News

> Nuclea snatches up Wilex AG Dx subsidiary. Story

> T2 jumps into pivotal trial for Candida assay. News

> NanoString gains FDA blessing for in vitro breast cancer assay. Report

> FDA cites Dx maker Dako for quality system violations. Article

> Study: Abbott blood test spots more female heart attack risks. Item

And Finally... A new study finds that while target cancer drugs are doing more to extend and save patients lives, their complexity is keeping some patients from getting the best care available. Story